CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 42 enrolled
Drug / intervention
LY2886721 +1 moredrug
Likely dose
LY2886721 5 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01227252
NCT01227252Phase 1Completed
CompareCT.gov

Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Oct 25, 2010·Updated Jul 19, 2019

In Brief

A Phase 1 clinical trial evaluating LY2886721 and Placebo for Alzheimer's Disease. Completed, enrolled 42 participants across 1 site.

Detailed Summary

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 25, 2010
Enrollment StartDec 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.7 years ago

Interventions

LY2886721drug

5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days

Placebodrug

Administered orally as capsules, daily for 14 days